Reported 8 months ago
Shin Po Pharmaceutical (6535) benefited from the nearing completion of the phase three clinical trial of new drug LT3001 for treating acute ischemic stroke, with a chance to unblind by the end of the year. This news propelled the stock price to surge gap up to the limit up at 208 NTD on June 17, with a trading volume of 2,831 shares. If it can hold above 200 NTD, it is likely to continue its upward momentum. The company has obtained drug approvals in six countries for the long-acting analgesic injection LT1001, and the highly anticipated LT3001 has seen faster-than-expected progress in clinical trials in China.
Source: YAHOO